Lipid-lowering medication

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country
0 on aging of 1 trial, 1 with no results posted

Human trial1

Outcomes

LDL-C

downin humans1

1 study

Lipid-lowering medication decreases LDL-C in humans (-0.76 mmol/L (-21%)).
“During the 36-month follow-up, the mean LDL-C values decreased statistically significantly in group 3 (-0.76 mmol/L, 95% CI -0.90 to -0.62, -21%, p < .001: [ANCOVA]).”
Human trialGroup 3 baseline LDL-C > 2.6 mmol/L36-monthn = 507
Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up
Scandinavian journal of primary health care15 Sep 2026

Trials

0 on aging of 1

In trials

Hypertriglyceridemia
Phase 2Completed1 trial

Trial sponsors

Grace Therapeutics
Company1 trialPhase 2289 people

Latest

1 in 12 months

Scandinavian Journal of Primary Health Care15 Sep

Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up

Non-randomised trial in 507 peopleDiabetes

Paper